BridgeBio Pharma [BBIO] vs Regeneron [REGN] Detailed Stock Comparison

BridgeBio Pharma

NASDAQ

Regeneron

NASDAQ

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: BridgeBio Pharma wins in 9 metrics, Regeneron wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric	BridgeBio Pharma	Regeneron	Better
P/E Ratio (TTM)	-17.12	14.95	BridgeBio Pharma
Price-to-Book Ratio	-5.28	2.06	BridgeBio Pharma
Debt-to-Equity Ratio	-1.04	9.04	BridgeBio Pharma
PEG Ratio	-0.12	13.09	BridgeBio Pharma
EV/EBITDA	-17.18	12.21	BridgeBio Pharma
Profit Margin (TTM)	98.25%	31.37%	BridgeBio Pharma
Operating Margin (TTM)	-120.72%	29.64%	Regeneron
EBITDA Margin (TTM)	N/A	29.64%	N/A
Return on Equity	36.76%	15.34%	BridgeBio Pharma
Return on Assets (TTM)	-41.96%	6.66%	Regeneron
Free Cash Flow (TTM)	$-529.63M	$3.54B	Regeneron
Dividend Yield	N/A	0.46%	N/A
1-Year Return	93.99%	-50.84%	BridgeBio Pharma
Price-to-Sales Ratio (TTM)	40.63	4.42	Regeneron
Enterprise Value	$10.71B	$54.52B	Regeneron
EV/Revenue Ratio	45.43	3.84	Regeneron
Gross Profit Margin (TTM)	96.70%	85.58%	BridgeBio Pharma
Revenue per Share (TTM)	$1	$133	Regeneron
Earnings per Share (Diluted)	$-4.13	$39.68	Regeneron
Beta (Stock Volatility)	1.23	0.33	Regeneron

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

BridgeBio Pharma vs Regeneron Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
BridgeBio Pharma	-2.29%	-4.36%	7.23%	48.86%	35.39%	74.04%
Regeneron	-1.45%	1.56%	5.09%	-1.23%	-17.35%	-17.58%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
BridgeBio Pharma	93.99%	368.51%	65.93%	82.05%	82.05%	82.05%
Regeneron	-50.84%	-1.12%	-2.18%	9.83%	2,487.71%	7,770.23%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

BridgeBio Pharma (BBIO): View Full Stock Overview

Regeneron (REGN): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: BridgeBio Pharma vs Regeneron

Metric	BBIO	REGN
Market Information
Market Cap i	$9.58B	$62.88B
Market Cap Category	Mid cap	Large cap
10 Day Avg. Volume i	1,945,004	859,422
90 Day Avg. Volume i	2,637,425	933,271
Last Close	$49.08	$589.48
52 Week Range	$21.72 - $51.86	$476.49 - $1,211.20
% from 52W High	-5.36%	-51.33%
All-Time High	$73.50 (Feb 08, 2021)	$1,211.20 (Aug 26, 2024)
% from All-Time High	-33.22%	-51.33%
Growth Metrics
Quarterly Revenue Growth	50.00%	0.04%
Quarterly Earnings Growth	50.00%	-0.03%
Financial Health
Profit Margin (TTM) i	0.98%	0.31%
Operating Margin (TTM) i	-1.21%	0.30%
Return on Equity (TTM) i	0.37%	0.15%
Debt to Equity (MRQ) i	-1.04	9.04
Cash & Liquidity
Book Value per Share (MRQ)	$-9.35	$287.55
Cash per Share (MRQ)	$3.96	$72.04
Operating Cash Flow (TTM) i	$-655,808,000	$4.74B
Levered Free Cash Flow (TTM) i	$-297,633,248	$2.85B
Dividends
Last 12-Month Dividend Yield i	N/A	0.46%
Last 12-Month Dividend i	N/A	$2.64

Valuation & Enterprise Metrics Analysis: BridgeBio Pharma vs Regeneron

Metric	BBIO	REGN
Price Ratios
P/E Ratio (TTM) i	-17.12	14.95
Forward P/E i	-16.38	13.09
PEG Ratio i	-0.12	13.09
Price to Sales (TTM) i	40.63	4.42
Price to Book (MRQ) i	-5.28	2.06
Market Capitalization
Market Capitalization i	$9.58B	$62.88B
Enterprise Value i	$10.71B	$54.52B
Enterprise Value Metrics
Enterprise to Revenue i	45.43	3.84
Enterprise to EBITDA i	-17.18	12.21
Risk & Other Metrics
Beta i	1.23	0.33
Book Value per Share (MRQ) i	$-9.35	$287.55

Financial Statements Comparison: BridgeBio Pharma vs Regeneron

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	BBIO	REGN
Revenue/Sales i	$116.63M	$3.03B
Cost of Goods Sold i	$2.64M	$464.30M
Gross Profit i	$113.99M	$2.56B
Research & Development i	$111.43M	$1.34B
Operating Income (EBIT) i	$-103.80M	$591.70M
EBITDA i	$-104.46M	$900.90M
Pre-Tax Income i	$-169.61M	$905.00M
Income Tax i	N/A	$96.30M
Net Income (Profit) i	$-169.61M	$808.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	BBIO	REGN
Cash & Equivalents i	$540.60M	$3.09B
Total Current Assets i	$695.17M	$17.57B
Total Current Liabilities i	$152.11M	$3.57B
Long-Term Debt i	$1.85B	$2.70B
Total Shareholders Equity i	$-1.64B	$29.39B
Retained Earnings i	$-3.26B	$32.38B
Property, Plant & Equipment i	$13.86M	N/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	BBIO	REGN
Operating Cash Flow i	$-215.45M	$1.36B
Capital Expenditures i	$0	N/A
Free Cash Flow i	$-200.83M	$773.60M
Debt Repayment i	$-459.00M	N/A
Common Stock Repurchase i	$-50.05M	$-1.05B

Short Interest & Institutional Ownership Analysis

Metric	BBIO	REGN
Shares Short i	18.52M	2.29M
Short Ratio i	7.46	2.55
Short % of Float i	0.16%	0.02%
Average Daily Volume (10 Day) i	1,945,004	859,422
Average Daily Volume (90 Day) i	2,637,425	933,271
Shares Outstanding i	190.04M	109.62M
Float Shares i	151.20M	97.89M
% Held by Insiders i	0.05%	0.02%
% Held by Institutions i	1.02%	0.91%

Dividend Analysis & Yield Comparison: BridgeBio Pharma vs Regeneron

Metric	BBIO	REGN
Last 12-Month Dividend i	N/A	$2.64
Last 12-Month Dividend Yield i	N/A	0.46%
3-Year Avg Annual Dividend i	N/A	$0.88
3-Year Avg Dividend Yield i	N/A	0.14%
3-Year Total Dividends i	N/A	$2.64
Ex-Dividend Date	N/A	Aug 18, 2025

BridgeBio Pharma [BBIO] vs Regeneron [REGN] Detailed Stock Comparison